Systemic Steroids and the Risk of Vasoocclusive Events in Patients with Sickle Cell Disease.
作者信息
Cohen Robyn T, Klings Elizabeth S
机构信息
The Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts.
Pediatrics - Pulmonary and Allergy Clinic, Boston Medical Center, Boston, Massachusetts; and.
出版信息
Ann Am Thorac Soc. 2023 Jan;20(1):18-20. doi: 10.1513/AnnalsATS.202207-627PS.
Abstract
摘要
相似文献
1
Systemic Steroids and the Risk of Vasoocclusive Events in Patients with Sickle Cell Disease.全身性类固醇与镰状细胞病患者血管闭塞性事件的风险
Ann Am Thorac Soc. 2023 Jan;20(1):18-20. doi: 10.1513/AnnalsATS.202207-627PS.
2
Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature.抗血小板和抗凝药物对镰状细胞病血管阻塞和血栓并发症的影响：文献综述。
Am J Health Syst Pharm. 2010 Jun 1;67(11):895-900. doi: 10.2146/ajhp090229.
3
Studies on the management and prevention of vasoocclusive crisis in sickle cell disease.镰状细胞病血管闭塞性危象的管理与预防研究
J Med. 1984;15(5-6):385-407.
4
Low-molecular-weight heparins for managing vasoocclusive crises in people with sickle cell disease: a summary of a cochrane systematic review.低分子量肝素用于治疗镰状细胞病患者的血管闭塞性危象：Cochrane系统评价综述
Hemoglobin. 2014;38(3):221-3. doi: 10.3109/03630269.2014.911748.
5
Vasoocclusive diseases of the posterior pole.
Int Ophthalmol Clin. 1981 Fall;21(3):201-13. doi: 10.1097/00004397-198102130-00016.
6
Monocyte phagocytic activity in sickle cell disease.镰状细胞病中的单核细胞吞噬活性。
Acta Haematol. 1991;85(4):199-201. doi: 10.1159/000204892.
7
Ultrasonography: can it differentiate between vasoocclusive crisis and acute osteomyelitis in sickle cell disease?超声检查：能否区分镰状细胞病中的血管阻塞性危机和急性骨髓炎？
J Pediatr Orthop. 1998 Jul-Aug;18(4):552-4.
8
Vascular risk assessment in patients with sickle cell disease.镰状细胞病患者的血管风险评估
Haematologica. 2011 Jan;96(1):1-5. doi: 10.3324/haematol.2010.035097.
9
Sickle cell vasoocclusion: many issues and some answers.镰状细胞血管阻塞：诸多问题与一些答案
Experientia. 1993 Jan 15;49(1):5-15. doi: 10.1007/BF01928783.
10
New concepts in assessing sickle cell disease severity.评估镰状细胞病严重程度的新概念。
Am J Hematol. 1998 May;58(1):61-6. doi: 10.1002/(sici)1096-8652(199805)58:1<61::aid-ajh11>3.0.co;2-8.
引用本文的文献
1
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.镰状细胞病（SCD）患者接受crizanlizumab 治疗时输注相关反应（IRR）管理的专家共识：RAND/UCLA 改良 Delphi 小组。
Ann Hematol. 2024 Jun;103(6):1909-1917. doi: 10.1007/s00277-024-05736-6. Epub 2024 Apr 20.
2
Fat Embolization Syndrome Secondary to Steroid Treatment in a Case of Sickle Cell Vaso-Occlusive Crisis.镰状细胞血管闭塞性危象患者接受类固醇治疗继发脂肪栓塞综合征
Case Rep Hematol. 2023 Jul 3;2023:5530870. doi: 10.1155/2023/5530870. eCollection 2023.
本文引用的文献
1
Sickle Cell Disease: A Review.镰状细胞病：综述。
JAMA. 2022 Jul 5;328(1):57-68. doi: 10.1001/jama.2022.10233.
2
Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease.镰状细胞病患者暴露于皮质类固醇后发生血管闭塞性事件的风险。
Blood. 2022 Jun 30;139(26):3771-3777. doi: 10.1182/blood.2021014473.
3
Benefit of pulmonary subspecialty care for children with sickle cell disease and asthma.肺部专科护理对镰状细胞病和哮喘儿童的益处。
Pediatr Pulmonol. 2022 Apr;57(4):885-893. doi: 10.1002/ppul.25845. Epub 2022 Feb 4.
4
Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease.合并症是镰状细胞病儿童和成人住院和发生严重 COVID-19 疾病的危险因素。
Blood Adv. 2021 Jul 13;5(13):2717-2724. doi: 10.1182/bloodadvances.2021004288.
5
Feasibility and preliminary outcomes of an integrated pediatric sickle cell disease and pulmonary care clinic for children with sickle cell disease.小儿镰状细胞病与肺部疾病一体化诊疗诊所用于镰状细胞病患儿的可行性及初步结果
Pediatr Blood Cancer. 2020 Nov;67(11):e28672. doi: 10.1002/pbc.28672. Epub 2020 Sep 4.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
7
Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations.2019冠状病毒病大流行期间血红蛋白异常患者的护理：建议概述
Am J Hematol. 2020 Aug;95(8):E208-E210. doi: 10.1002/ajh.25857. Epub 2020 May 21.
8
Corticosteroid-induced vaso-occlusive events may be prevented by lowering hemoglobin S levels in adults with sickle cell disease.通过降低镰状细胞病成人患者的血红蛋白S水平，可预防皮质类固醇诱导的血管闭塞事件。
Transfus Apher Sci. 2017 Oct;56(5):717-718. doi: 10.1016/j.transci.2017.08.005. Epub 2017 Sep 2.
9
Severe Vaso-Occlusive Episodes Associated with Use of Systemic Corticosteroids in Patients with Sickle Cell Disease.镰状细胞病患者使用全身性皮质类固醇激素相关的严重血管闭塞性发作
J Natl Med Assoc. 2008 Aug;100(8):948-951. doi: 10.1016/S0027-9684(15)31410-3.
10
Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: A triple-blind, randomized trial.吸入性类固醇可降低镰状细胞病患者的疼痛和可溶性血管细胞黏附分子水平：一项三盲随机试验。
Am J Hematol. 2017 Jul;92(7):622-631. doi: 10.1002/ajh.24742. Epub 2017 Jun 5.
Zotero 插件